OPTIMAL DOSE OF TOCILIZUMAB FOR THE TREATMENT OF GIANT CELL ARTERITIS: EFFICACY, SAFETY, AND EXPOSURE-EFFICACY ANALYSIS FROM GIACTA

Stone JH, Tuckwell K, Dimonaco S, Klearman M, Mallalieu NL, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Book Volume: 76

Pages Range: 107-108

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

Roche Products Limited and Roche Diagnostics Limited

United Kingdom (GB) Roche Deutschland Holding GmbH

Germany (DE) Harvard University

United States (USA) (US) Arcispedale Santa Maria Nuova

Italy (IT) Ludwig-Maximilians-Universität (LMU)

Germany (DE) University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven

Belgium (BE) University of Groningen / Rijksuniversiteit Groningen

Netherlands (NL) Hospital for Special Surgery (HSS)

United States (USA) (US) Genentech Inc.

United States (USA) (US) Southend Hospital

United Kingdom (GB) Universitat de Barcelona (UB) / University of Barcelona

Spain (ES)

How to cite

APA:

Stone, J.H., Tuckwell, K., Dimonaco, S., Klearman, M., Mallalieu, N.L., Aringer, M.,... Collinson, N. (2017). OPTIMAL DOSE OF TOCILIZUMAB FOR THE TREATMENT OF GIANT CELL ARTERITIS: EFFICACY, SAFETY, AND EXPOSURE-EFFICACY ANALYSIS FROM GIACTA. (pp. 107-108).

MLA:

Stone, J. H., et al. "OPTIMAL DOSE OF TOCILIZUMAB FOR THE TREATMENT OF GIANT CELL ARTERITIS: EFFICACY, SAFETY, AND EXPOSURE-EFFICACY ANALYSIS FROM GIACTA." 2017. 107-108.

BibTeX: Download